AV-LEAN: TH9507 (GHRH Analogue) Research Peptide

AV-LEAN is a research peptide formulation identified by the development code TH9507. The compound is a synthetic analogue of human growth hormone-releasing hormone (GHRH).

TH9507 retains the full 44-amino-acid sequence of human growth hormone-releasing factor while incorporating a trans-3-hexenoyl group at its amino terminus. This structural modification distinguishes the synthetic analogue from the naturally occurring hormone.

The Discovery of Human Growth Hormone-Releasing Factor

The naturally occurring hormone that served as the foundation for TH9507 was characterized in 1982.

In November of that year, Guillemin and colleagues published research in Science describing a 44-amino-acid growth hormone-releasing factor with a C-terminal amide group.

This 44-residue chain forms the structural foundation of TH9507, which retains the sequence while incorporating an additional modification at the amino terminus.

View Guillemin et al. (1982), Science

During the same year, Spiess and colleagues reported a related 40-residue free-acid form of growth hormone-releasing factor.

Their research also examined shorter synthetic peptide sequences, including a 1–29 amide fragment, which demonstrated comparable activity to the longer peptide in their in vitro assays.

View Spiess et al. (1982), Biochemistry

Why the Amino Terminus Matters

Research into naturally occurring growth hormone-releasing factor identified the amino-terminal region as an important site of enzymatic degradation.

In 1986, Frohman and colleagues investigated the stability of the 44-residue hormone following incubation in human plasma.

The researchers traced degradation to a dipeptidylaminopeptidase that removed the first two amino acid residues, tyrosine and alanine (Tyr-Ala), from the peptide’s amino terminus.

View Frohman et al. (1986), Journal of Clinical Investigation

TH9507 Structural Modification

TH9507 was developed with a targeted modification intended to address the susceptibility of the natural hormone’s amino terminus to enzymatic breakdown.

The molecule retains the human growth hormone-releasing factor 1–44 amide sequence, with a trans-3-hexenoyl group attached to the first amino acid residue, tyrosine.

2007 Research on Enzymatic Stability

Ferdinandi and colleagues published research in Basic & Clinical Pharmacology & Toxicology in 2007 describing the synthetic GHRH analogue under the development designation TH9507.

The investigators characterized the molecule as hGRF(1–44)-NH2 with a trans-3-hexenoyl modification at the first tyrosine residue.

Their experiments reported resistance to deactivation by dipeptidyl aminopeptidase-IV and slower in vitro degradation compared with the natural hormone in rat, dog, and human plasma.

The publication also included animal pharmacology and toxicology investigations, providing additional preclinical characterization of the synthetic analogue.

View Ferdinandi et al. (2007), Basic & Clinical Pharmacology & Toxicology

Chemical Identity and Research Documentation

The investigational compound identified as TH9507 is listed in PubChem under CID 16137828, with the molecular formula C221H366N72O67S, an approximate computed molecular weight of 5136 g/mol, and CAS number 218949-48-5.

The FDA substance record identifies the same compound under UNII MQG94M5EEO and documents its peptide sequence and terminal modifications.

An acetate salt form is separately identified in regulatory substance records. Without verified batch-specific documentation, the exact chemical or salt form of an individual research vial cannot be established solely from its product designation.

View Compound Record on PubChem

|

View FDA Substance Record